Pretreatment assessment of hepatocellular cancer: expert consensus conference.
作者信息
Wilson Stephanie R, Greig Paul, Kaseb Ahmed O
机构信息
Department of Radiology, University of Calgary, Calgary, Canada.
出版信息
HPB (Oxford). 2010 Jun;12(5):300-1. doi: 10.1111/j.1477-2574.2010.00187.x.
Abstract
摘要
相似文献
1
Pretreatment assessment of hepatocellular cancer: expert consensus conference.肝细胞癌的预处理评估：专家共识会议
HPB (Oxford). 2010 Jun;12(5):300-1. doi: 10.1111/j.1477-2574.2010.00187.x.
2
Pretreatment assessment of hepatocellular carcinoma: expert consensus statement.肝细胞癌的预处理评估：专家共识声明。
HPB (Oxford). 2010 Jun;12(5):289-99. doi: 10.1111/j.1477-2574.2010.00181.x.
3
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.肝细胞癌联合治疗的非手术疗法：专家共识会议
HPB (Oxford). 2010 Jun;12(5):321-2. doi: 10.1111/j.1477-2574.2010.00186.x.
4
Surgical treatment of hepatocellular cancer: expert consensus conference.肝细胞癌的外科治疗：专家共识会议
HPB (Oxford). 2010 Jun;12(5):311-2. doi: 10.1111/j.1477-2574.2010.00188.x.
5
Imaging diagnosis and staging of hepatocellular carcinoma.肝细胞癌的影像学诊断与分期
Liver Transpl. 2011 Oct;17 Suppl 2:S34-43. doi: 10.1002/lt.22369.
6
AHPBA/SSO/SSAT sponsored Consensus Conference on Multidisciplinary Treatment of Hepatocellular Carcinoma.美国肝脏胰胆协会/外科肿瘤学会/肉瘤及软组织肿瘤学会主办的肝细胞癌多学科治疗共识会议。
HPB (Oxford). 2010 Jun;12(5):287-8. doi: 10.1111/j.1477-2574.2010.00184.x.
7
Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?肝细胞癌降期后患者是否符合肝移植条件？
Liver Transpl. 2011 Oct;17 Suppl 2:S109-16. doi: 10.1002/lt.22335.
8
What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?对于肝移植背景下的肝细胞癌，最佳的分期系统是什么？
Liver Transpl. 2011 Oct;17 Suppl 2:S26-33. doi: 10.1002/lt.22352.
9
[Comparison of the clinical practice guidelines for hepatocellular carcinoma in Japan and Western countries].[日本与西方国家肝细胞癌临床实践指南的比较]
Nihon Geka Gakkai Zasshi. 2008 Nov;109(6):343-8.
10
[Imaging techniques in hepatocellular carcinoma: diagnosis, extension and evaluation of therapeutic response].[肝细胞癌的成像技术：诊断、范围及治疗反应评估]
Gastroenterol Hepatol. 2010 Dec;33(10):721-6. doi: 10.1016/j.gastrohep.2010.01.012. Epub 2010 May 5.
引用本文的文献
1
Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.胰岛素样生长因子1/Child-Turcotte-Pugh综合评分作为索拉非尼治疗晚期肝细胞癌患者治疗结局的预测指标
Oncotarget. 2021 Apr 13;12(8):756-766. doi: 10.18632/oncotarget.27924.
2
Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular Carcinoma.剪切波弹性成像评估肝脏硬度预测肝细胞癌患者术后肝功能衰竭。
J Gastrointest Surg. 2017 Sep;21(9):1471-1479. doi: 10.1007/s11605-017-3443-9. Epub 2017 May 16.
3
Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma.I 型胰岛素样生长因子作为肝癌肝储备评估工具。
J Hepatocell Carcinoma. 2015 Sep 18;2:131-42. doi: 10.2147/JHC.S81309. eCollection 2015.
4
Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma.用于评估埃及肝细胞癌患者肝储备功能的IGF-CTP评分系统的验证
Oncotarget. 2015 Aug 28;6(25):21193-207. doi: 10.18632/oncotarget.4176.
5
Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.胰岛素样生长因子-1 评分评估肝细胞癌肝储备功能的建立与验证。
J Natl Cancer Inst. 2014 May 9;106(5):dju088. doi: 10.1093/jnci/dju088.
6
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.血浆胰岛素样生长因子-1 和血管内皮生长因子与肝细胞癌患者的临床和预后意义。
J Clin Oncol. 2011 Oct 10;29(29):3892-9. doi: 10.1200/JCO.2011.36.0636. Epub 2011 Sep 12.
本文引用的文献
1
Pretreatment assessment of hepatocellular carcinoma: expert consensus statement.肝细胞癌的预处理评估：专家共识声明。
HPB (Oxford). 2010 Jun;12(5):289-99. doi: 10.1111/j.1477-2574.2010.00181.x.
2
Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry.301 例连续扩大右半肝切除术：基于系统肝体积测量的结果评估。
Ann Surg. 2009 Oct;250(4):540-8. doi: 10.1097/SLA.0b013e3181b674df.
3
Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation.超声造影下肝细胞癌的增强模式：与组织学分化的比较
Radiology. 2007 Sep;244(3):898-906. doi: 10.1148/radiol.2443061520.
4
Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome.肝大部切除术前门静脉栓塞及其对肝脏再生、可切除性和预后的影响。
Br J Surg. 2007 Nov;94(11):1386-94. doi: 10.1002/bjs.5836.
5
Management of hepatocellular carcinoma.肝细胞癌的管理
Hepatology. 2005 Nov;42(5):1208-36. doi: 10.1002/hep.20933.
6
Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation.使用第二代超声造影剂声诺维评估肝细胞癌：与细胞分化的相关性
Eur Radiol. 2004 Jun;14(6):1092-9. doi: 10.1007/s00330-004-2298-0. Epub 2004 Mar 9.
7
Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors.肝脏体积和肝功能储备的测量作为肝肿瘤切除手术决策的指导
Hepatology. 1997 Nov;26(5):1176-81. doi: 10.1053/jhep.1997.v26.pm0009362359.
Zotero 插件